A novel target for type 1 diabetes
A novel target for type 1 diabetes
批准号:
8012354
负责人:
Deyu Fang
金额:
$9.77万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-03-01 至 2010-05-31
关键词:
Autoimmune DiseasesAutoimmune ProcessAutoimmunityBeta CellCellsDevelopmentFailureImmuneImmune responseInbred NOD MiceInsulin-Dependent Diabetes MellitusLaboratoriesMaintenanceMolecularMusPancreasPilot ProjectsPreventiveReagentResearchResveratrolStagingT-Cell ActivationT-LymphocyteTCF Transcription FactorTherapeuticnovelperipheral tolerancesmall molecule
中文摘要
1型糖尿病(T1D)是一种自身免疫性疾病,由胰岛素分泌的永久性破坏引起
胰腺中的β细胞通过自我攻击免疫细胞。这些自我攻击的免疫T细胞
一般在开发阶段就被淘汰,如果发生任何泄漏,应该在外围容忍。
因此,T细胞耐受性的诱导/维持失败对T1D至关重要。然而,分子
诱导/维持T细胞耐受的机制在很大程度上仍不清楚。在这里我们找到了
Sirt1功能的丧失会导致免疫反应异常升高和外周血细胞崩溃
T细胞的耐受性。结果,Sirt1-/-小鼠产生了自发的自身免疫。那些结果
提示Sirt1是T细胞激活的负性调节因子,是维持T细胞耐受所必需的。它是
因此,没有Sirt1的小鼠可能会患上T1D。Sirt1被小分子激活,如
白藜芦醇可以通过抑制攻击β细胞的自身免疫T细胞来潜在地用于治疗T1D。的确,
我们实验室的一项初步研究结果表明,Sirt1的激活剂白藜芦醇对NOD小鼠具有保护作用
来自T1D。
因此,这项提议旨在确定Sirt1如何发挥作用的分子机制。
T细胞无能因子,并研究Sirt1功能失调如何参与糖尿病的发生发展。
T1D。我们还将进一步确定白藜芦醇对T1D的预防/治疗作用。
我们提出的研究结果可能揭示T细胞耐受的一种新的分子机制。
这项研究还将确定治疗T1D的潜在治疗试剂。
英文摘要
The type 1 diabetes (T1D) is an autoimmune disease that is caused by the permanent destruction of insulinproducing
beta cells in pancreas by self-attacking immune cells. These self-attacking immune T cells are
generally eliminated during development stage, and should be tolerized in the periphery if any leaking occurs.
Therefore, a failure in the induction/maintenance of T-cell tolerance is crucial for T1D. However, the molecular
mechanisms by which T-cell tolerance is induced/maintained remain largely unknown. Here we have found
that loss of Sirt1 functions causes abnormally elevated immune responses and a break-down of peripheral
tolerance of T cells. As a consequence, Sirt1-/- mice develop spontaneous autoimmunity. Those results
indicate that Sirt1 is a negative regulator of T-cell activation and is required to maintain T-cell tolerance. It is
therefore possible that mice without Sirt1 may develop T1D. Activation of Sirt1 by small molecules like
resveratrol can potentially be used to treat T1D by inhibiting beta-cell-attacking autoimmune T cells. Indeed,
results from a pilot study in our laboratory indicate that the activator of Sirt1, resveratrol, protected NOD mice
from T1D.
Therefore, this proposal aims to determine the molecular mechanisms underlying how Sirt1 functions an
anergic factor of T-cells, and to investigate how dysregulated Sirt1 functions are involved in the development of
T1D. We will also further determine the preventive/treating effects of resveratrol on T1D.
Results from our proposed research are likely to uncover a novel molecular mechanism of T-cell tolerance.
This study will also indentify potential therapeutic reagents for T1D.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
VPS72 controls Treg cell stability and adaptation to tumor microenvironment
-
批准号:10754017
-
项目类别:
-
资助金额:$65.81万
-
财政年份:2023
-
负责人:Deyu Fang
-
依托单位:
Clinical analysis and therapeutic development of exosomal ACE2
-
批准号:10531071
-
项目类别:
-
资助金额:$77.94万
-
财政年份:2022
-
负责人:Deyu Fang
-
依托单位:
Clinical analysis and therapeutic development of exosomal ACE2
-
批准号:10666589
-
项目类别:
-
资助金额:$74.85万
-
财政年份:2022
-
负责人:Deyu Fang
-
依托单位:
A deubiquitination module controls Treg adaptation to tumor microenvironment
-
批准号:10152123
-
项目类别:
-
资助金额:$56.16万
-
财政年份:2021
-
负责人:Deyu Fang
-
依托单位:
A deubiquitination module controls Treg adaptation to tumor microenvironment
-
批准号:10545001
-
项目类别:
-
资助金额:$55.21万
-
财政年份:2021
-
负责人:Deyu Fang
-
依托单位:
Regulation of Rhythmic m6A RNA Modification by ER‐associated Degradation
-
批准号:10297978
-
项目类别:
-
资助金额:$57.48万
-
财政年份:2021
-
负责人:Deyu Fang
-
依托单位:
Regulation of Rhythmic m6A RNA Modification by ER‐associated Degradation
-
批准号:10615181
-
项目类别:
-
资助金额:$54.91万
-
财政年份:2021
-
负责人:Deyu Fang
-
依托单位:
A deubiquitination module controls Treg adaptation to tumor microenvironment
-
批准号:10320965
-
项目类别:
-
资助金额:$55.35万
-
财政年份:2021
-
负责人:Deyu Fang
-
依托单位:
Regulation of Rhythmic m6A RNA Modification by ER‐associated Degradation
-
批准号:10454294
-
项目类别:
-
资助金额:$55.86万
-
财政年份:2021
-
负责人:Deyu Fang
-
依托单位:
Targeting a Treg deubiquitinase in antitumor immune therapy
-
批准号:10429984
-
项目类别:
-
资助金额:$34.51万
-
财政年份:2018
-
负责人:Deyu Fang
-
依托单位:
Novel Role of Hepatic SEL1L-HRD1 ERAD in FGF21 Gene Transcription
-
批准号:9792378
-
项目类别:
-
资助金额:$53.04万
-
财政年份:2018
-
负责人:Deyu Fang
-
依托单位:
Novel Role of Hepatic SEL1L-HRD1 ERAD in Bile Acid Metabolism
-
批准号:10584953
-
项目类别:
-
资助金额:$70.04万
-
财政年份:2018
-
负责人:Deyu Fang
-
依托单位:
Targeting a Treg deubiquitinase in antitumor immune therapy
-
批准号:10197845
-
项目类别:
-
资助金额:$35.22万
-
财政年份:2018
-
负责人:Deyu Fang
-
依托单位:
Simultaneous Targeting of IRE1a in B Cells and Macrophages for Lupus Therapy
-
批准号:8751549
-
项目类别:
-
资助金额:$35.07万
-
财政年份:2014
-
负责人:Deyu Fang
-
依托单位:
The roles of Synoviolin in immune tolerance and autoimmunity
-
批准号:8890108
-
项目类别:
-
资助金额:$37.95万
-
财政年份:2014
-
负责人:Deyu Fang
-
依托单位:
Simultaneous Targeting of IRE1a in B Cells and Macrophages for Lupus Therapy
-
批准号:9293889
-
项目类别:
-
资助金额:$33.88万
-
财政年份:2014
-
负责人:Deyu Fang
-
依托单位:
The roles of Synoviolin in immune tolerance and autoimmunity
-
批准号:8756545
-
项目类别:
-
资助金额:$37.95万
-
财政年份:2014
-
负责人:Deyu Fang
-
依托单位:
The roles of Synoviolin in immune tolerance and autoimmunity
-
批准号:9089984
-
项目类别:
-
资助金额:$37.95万
-
财政年份:2014
-
负责人:Deyu Fang
-
依托单位:
The roles of Sirt1, a deacetylase, in immune tolerance and autoimmunity
-
批准号:8147894
-
项目类别:
-
资助金额:$18.0万
-
财政年份:2010
-
负责人:Deyu Fang
-
依托单位:
A novel target for type 1 diabetes
-
批准号:8139429
-
项目类别:
-
资助金额:$0.23万
-
财政年份:2008
-
负责人:Deyu Fang
-
依托单位: